Who
Leone D. Patterson
Director
Company insider
Files Form 4 as: Director, Nkarta; Director, Kalaris Therapeutics; EVP, Chief Bus & Fin Officer, Zymeworks; Chief Fin. and Bus. Officer, Tenaya Therapeutics; Director, Climb Bio; President and CFO, Adverum Biotechnologies; Chief Financial Officer, diaDexus; Vice President, CFO, Transcept Pharmaceuticals.
In numbers
- Trades disclosed
- 64
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $2.2M
- Companies
- 8
- Companies where not an officer
- 3
- First trade
- 25 Jun 2012
- Last trade
- 10 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 11 Jun 2026 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code A | $4,842459 at $10.55 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code A | $4,842459 at $10.55 | filing |
| 5 Jun 2025filed 9 Jun 2025 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,000 at $0.00 | filing |
| 10 Apr 2025filed 11 Apr 2025 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 10 Jan 2025filed 10 Jan 2025 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —79,000 at $0.00 | filing |
| 10 Jan 2025filed 10 Jan 2025 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,000 at $0.00 | filing |
| 1 Sep 2024filed 3 Sep 2024 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —360,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 23 Feb 2024filed 27 Feb 2024 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —205,000 at $0.00 | filing |
| 23 Feb 2024filed 27 Feb 2024 | TNYA Tenaya TherapeuticsBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 16 Feb 2024filed 16 Feb 2024 | TNYA Tenaya TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K5,201 at $5.86 | filing |
| 16 Aug 2023filed 18 Aug 2023 | TNYA Tenaya TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K4,452 at $3.81 | filing |
| 7 Jun 2023filed 9 Jun 2023 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 15 Feb 2023filed 17 Feb 2023 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,000 at $0.00 | filing |
| 15 Feb 2023filed 17 Feb 2023 | TNYA Tenaya TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 15 Feb 2023filed 17 Feb 2023 | TNYA Tenaya TherapeuticsBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.